If only...
Pharmaceutical giant AstraZeneca (LSE: AZN) is expected to grow its earnings per share (EPS) in 2018, after four years of stagnant profits. Last month Astra reported that drug sales fell by 2% to $10bn (in constant currency terms) in the first half of 2018, while core operating profits were down 34% to $2.2bn. However, sales from new medicines rose by 69%, thanks largely to a strong performance from its cancer drugs including Tagrisso, which has benefited from its recent approval as the first-choice treatment for lung-cancer patients in Europe.
Be glad you didn't buy...
Mitie Group (LSE: MTO) provides services to owners and occupiers of commercial and industrial properties. The outsourcer, which was hit by several profit warnings and investigations by financial regulators last year, came under scrutiny after Carillion's collapse in January this year. However, in June it reported a pre-tax loss of £24.7m, down from £58.2m the previous year, while revenues rose 3.8% to £2.2bn. Mitie's chief executive Phil Bentley claims the firm's turnaround is on track and that it will return to profit this year as cost saving measures start to take effect.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Four AI ETFs to buyIs now a good time to buy AI ETFs? We examine four AI ETFs that investors might want to add to their portfolio
-
Chase boosts easy-access interest rate - savers could earn 4.75%Chase is offering a boosted interest rate which is fixed for six months, on top of the standard variable rate
-
AstraZeneca’s Covid troubles could see it pull out of making vaccinesNews AstraZeneca has suffered a series of setbacks with its Covid-19 jab and may exit the inoculation subsector altogether. Matthew Partridge reports
-
AstraZeneca’s shareholders rebel over payNews Shareholders in AstraZeneca have rebelled over proposals to raise bonus levels for its bosses.
-
Major setback for AstraZenecaFeatures Pharma giant AstraZeneca was banking on a key clinical trial for its cancer drugs. It was a flop. What comes next? asks Alice Gråhns.
-
A revolutionary new cancer treatment – and the blue-chip stock set to benefitFeatures A new kind of cancer therapy could make a big difference to survival rates - and transform the fortunes of one big UK drugs company. Matthew Partridge explains.
-
AstraZeneca fight rumbles onNews The proposed takeover of AstraZeneca is proving to be one of the most controversial yet.
-
Company in the news: AstraZenecaFeatures Drugs giant AstraZeneca is at the centre of a takeover tussle with US rival Pfizer. Phil Oakley looks at how the shares have been affected.
-
Buy Big Pharma – the deal spree could be just beginningFeatures With pharmaceutical stocks still looking cheap and some very smart deals being done, it’s a good time to buy in to the sector. John Stepek explains how.
